cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2017-4-68-75cardiovascular-661Research ArticleИССЛЕДОВАНИЯ И РЕГИСТРЫREGISTERS AND STUDIESНИЗКОДОЗОВЫЙ АСПИРИН: РАЗНООБРАЗИЕ ЛЕКАРСТВЕННЫХ ФОРМLOW DOSAGE ACETYLSALICYLIC ACID: A VARIETY OF FORMULATIONSРафальскийВ. В.RafalskyV. V.

д.м.н., профессор, профессор кафедры терапии, Смоленск;

руководитель центра клинических исследований, Калининград

Smolensk;

Kaliningrad

v.rafalskiy@mail.ruКриковаА. В.KrikovaA. V.

д.фарм.н., доцент, зав. кафедрой управления и экономики фармации,

Смоленск

Smolensk

ПавлюченковаН. А.PavlyuchenkovaN. A.

к.фарм.н., доцент кафедры управления и экономики фармации,

Смоленск

Smolensk

ФГБОУ ВО “Смоленский государственный медицинский университет” Минздрава России; ФГАОУ ВО “Балтийский федеральный университет имени Иммануила Канта”FSBEI HE “Smolensky State Medical University” of the Ministry of Health; FSAEI HE “Baltiysky Federal University named after Immanuil Kant”ФГБОУ ВО “Смоленский государственный медицинский университет” Минздрава РоссииFSBEI HE “Smolensky State Medical University” of the Ministry of Health2017200820171646875Copyright © Рафальский В.В., Крикова А.В., Павлюченкова Н.А., 20172017Рафальский В.В., Крикова А.В., Павлюченкова Н.А.Rafalsky V.V., Krikova A.V., Pavlyuchenkova N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/661

Наиболее распространенной лекарственной формой низкодозовых (нд) препаратов ацетилсалициловой кислоты (АСК) для профилактического применения является кишечнорастворимая таблетка — 80,6% в структуре препаратов ндАСК, зарегистрированных на мировом фармацевтическом рынке. Препараты ндАСК представлены в основном (84,4%) в виде монопрепаратов, содержащих в качестве активного действующего вещества только АСК, чаще всего в дозе 100 мг. Содержание 81 мг АСК в препаратах широкое распространение получило только в Северной Америке, что связано с использованием неметрической системы измерений. Комбинированные препараты ндАСК с нерастворимым антацидом (магния гидроксид) имеют в мире ограниченное применение — 1,6% от числа всех зарегистрированных на рынке препаратов, и используются преимущественно в странах бывшего СССР.

The most prevalent formulation of the low-dosage (ld) acetylsalicylic acid (ASA) for prevention purposes is the gut soluble pill — 80,6% of the ldASA registered in pharmacy market. Formulations of ldASA mostly presented as ASA monodrugs (84,4%), containing only ASA as active substance, predominantly as 100 mg dosage. Amount of ASA of 81 mg has become widespread only in North America, that is related to nonmetric measurement system. Combinational ldASA with non-soluble antacide (magnesium hydroxide) are not broadly used throughout the world — 1,6% of all pharmacy market registered labels, and mostly in use in the regions of former USSR.

ацетилсалициловая кислотапрофилактикасердечно-сосудистые заболеваниялекарственные формыанализ рынкаacetylsalicylic acidpreventioncardiovascular diseasesdrug formulationsmarketing analysisReferencesBerg J, Bjorck L, Lappas G, et al. Continuing decrease in coronary heart disease mortality in Sweden. BMC cardiovascular disorders 2014; 14: 9.Berg J, Bjorck L, Lappas G, et al. Continuing decrease in coronary heart disease mortality in Sweden. BMC cardiovascular disorders 2014; 14: 9.Stuntz M, Bernstein B. Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012-2015. Preventive medicine reports 2017; 5: 183-6.Stuntz M, Bernstein B. Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012-2015. Preventive medicine reports 2017; 5: 183-6.Bjorklund L, Wallander MA, Johansson S, et al. Aspirin in cardiology-benefits and risks. Int J Clin Pract 2009; 63(3): 468-77.Bjorklund L, Wallander MA, Johansson S, et al. Aspirin in cardiology-benefits and risks. Int J Clin Pract 2009; 63(3): 468-77.Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71-86.Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71-86.Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e89S-119.Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e89S-119.Bibbins-Domingo K, Force USPST. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2016; 164 (12): 836-45.Bibbins-Domingo K, Force USPST. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2016; 164 (12): 836-45.Ostergaard L, Fosbol EL, Roe MT. The Role of Antiplatelet Therapy in Primary Prevention. A Review. Curr Pharm Des 2017; 23 (9): 1294-306.Ostergaard L, Fosbol EL, Roe MT. The Role of Antiplatelet Therapy in Primary Prevention. A Review. Curr Pharm Des 2017; 23 (9): 1294-306.Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Ann Intern Med 2016.Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Ann Intern Med 2016.Cao Y, Nishihara R, Wu K, et al. Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. JAMA oncology 2016.Cao Y, Nishihara R, Wu K, et al. Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. JAMA oncology 2016.Chubak J, Kamineni A, Buist DSM, et al. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the US Preventive Services Task Force. Rockville (MD); 2015.Chubak J, Kamineni A, Buist DSM, et al. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the US Preventive Services Task Force. Rockville (MD); 2015.Rafalskiy V, Krikova A. Clinical pharmacology of acetylsalicylic acid and features of dosage forms — the key to effective and safe use for the prevention of thrombosis. Medicinsky Sovet 2016; (5): 26-33. Russian (Рафальский В.В., Крикова А.В. Клиническая фармакология ацетилсалициловой кислоты и особенности лекарственных форм — ключ к эффективному и безопасному применению для профилактики тромбозов. Медицинский Совет 2016; 5: 26-33).Rafalskiy V, Krikova A. Clinical pharmacology of acetylsalicylic acid and features of dosage forms — the key to effective and safe use for the prevention of thrombosis. Medicinsky Sovet 2016; (5): 26-33. Russian (Рафальский В.В., Крикова А.В. Клиническая фармакология ацетилсалициловой кислоты и особенности лекарственных форм — ключ к эффективному и безопасному применению для профилактики тромбозов. Медицинский Совет 2016; 5: 26-33).Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104 (3): 728-38.Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104 (3): 728-38.Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93 (11): 2037-46.Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93 (11): 2037-46.du Pre BC, van Laake LW. Buffered aspirin: what is your gut feeling? Netherlands Heart Journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2014; 22 (3): 105-6.du Pre BC, van Laake LW. Buffered aspirin: what is your gut feeling? Netherlands Heart Journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2014; 22 (3): 105-6.Jaspers Focks J, Tielemans MM, van Rossum LG, et al. Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin. Netherlands Heart Journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2014; 22 (3): 107-12.Jaspers Focks J, Tielemans MM, van Rossum LG, et al. Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin. Netherlands Heart Journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2014; 22 (3): 107-12.Takada M, Fujimoto M, Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int J Clin Pharmacol Ther 2014; 52 (3): 181-91.Takada M, Fujimoto M, Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int J Clin Pharmacol Ther 2014; 52 (3): 181-91.Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. JACC 2010; 56 (24): 2051-66.Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. JACC 2010; 56 (24): 2051-66.Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95 (10): 1218-22.Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95 (10): 1218-22.

The authors declare that there are no conflicts of interest present.